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Abstract The receptor-activity-modifying protein (RAMP) 1 is
a single-transmembrane-domain protein associated with the cal-
citonin-like receptor (CLR) to reveal a calcitonin gene-related
peptide (CGRP) receptor. The extracellular region of RAMP1
contains six conserved cysteines. Here, Cys27 in myc-tagged
human (h) RAMP1 was deleted (hRAMP1v1), and Cys40,
Cys57, Cys72, Cys82 and Cys104 were each replaced by Ala. In
COS-7 cells expressing hCLR/myc-hRAMP1v1 or -C82A, cell
surface expression, [125I]hKCGRP binding and cAMP forma-
tion in response to hKCGRP were similar to those of hCLR/
myc-hRAMP1. Cell surface expression of myc-hRAMP1-C72A
was reduced to 243 7% of myc-hRAMP1, and that of -C40A,
-C57A and -C104A was below 10%. [125I]hKCGRP binding
of hCLR/myc-hRAMP1-C72A was 133 3% of hCLR/myc-
hRAMP1 and it was undetectable in hCLR/myc-hRAMP1-
C40A-, -C57A- and -C104A-expressing cells. Maximal cAMP
stimulation by hKCGRP in hCLR/myc-hRAMP1-C40A- and
-C72A-expressing cells was 143 1% and 3332% of that of the
hCLR/myc-hRAMP1 with comparable EC50. But cAMP stim-
ulation was abolished in cells expressing hCLR/myc-hRAMP1-
C57A and -C104A. In conclusion, CGRP receptor function was
not a¡ected by the deletion of Cys27 or the substitution of Cys82
by Ala in hRAMP1, but it was impaired by the substitution of
Cys40, Cys57, Cys72 and Cys104 by Ala. These four cysteines are
required for the transport of hRAMP1 together with the CLR
to the cell surface.
: 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Receptor-activity-modifying proteins (RAMP) 1, -2 and -3
of man, rat, mouse and pig are single-transmembrane-domain
proteins required for the functional expression of the calcito-
nin-like receptors (CLR) [1^4]. CLR/RAMP1 and -2 hetero-
dimers are receptors for calcitonin gene-related peptide
(CGRP) and adrenomedullin (AM), respectively, and the
CLR/RAMP3 complex is an AM/CGRP receptor [5].
RAMP1, -2 and -3 exhibit 30% amino acid sequence similar-
ity. The extracellular domains of between 90 and 100 amino
acids de¢ne in part CGRP and AM selectivity of the CLR/
RAMP heterodimers [6].
RAMP2 and -3, unlike RAMP1, are N-glycosylated.
RAMP1, therefore di¡erent from RAMP2 and -3, requires
the CLR for the transport to the cell surface. Intracellular
retention of human (h) RAMP1 in the absence of the CLR
was overcome when the nine-amino acid intracellular tail was
shortened by eight amino acids, including a putative SKRT
retention signal conserved in RAMP1 [7]. Moreover, the
transport of mouse RAMP1 to the cell surface was revealed
in the absence of the CLR when N-glycosylation sites were
introduced into its extracellular domain [8].
RAMP1 contains six cysteines in the N-terminal extracellu-
lar domain in positions 27, 40, 57, 72, 82 and 104. They are
conserved in RAMP3. RAMP2 has only four cysteine residues
in the extracellular domain corresponding to Cys40, Cys57,
Cys72 and Cys104 of RAMP1. In hRAMP2 all four cysteines
are required for its expression at the cell surface [9]. In human
embryonic kidney (HEK) cells expressing hRAMP1 alone,
hRAMP1 dimers sensitive to dithiothreitol treatment were
recognised [10]. This suggested that intermolecular disulphide
bridges between cysteine residues were formed in the absence
of the CLR. Interestingly, the RAMP1 dimer/monomer ratio
decreased in the presence of the CLR. However, intermolec-
ular disulphide bridges in CLR/RAMP1 heterodimers have so
far not been identi¢ed [11]. Substitution of the sequence
Cys27^Ala50, including the second cysteine in position 40 of
hRAMP1, by the corresponding Asn36^Pro78 sequence of
hRAMP2 abolished cell surface expression and function of
the chimeric hRAMP2/1 coexpressed with the CLR [12].
The N-terminus of hRAMP1 is therefore required for its de-
livery to the cell surface together with the CLR.
In the present study, the functional role of the extreme N-
terminus of hRAMP1 and of the six cysteine residues was
investigated. Deletions of Cys27, Cys27^Asn31, Cys27^Arg37
and Cys27^Asp47, including Cys40, removed one, ¢ve, 11 and
21 N-terminal amino acids adjacent to the presumed signal
sequence in hRAMP1. Moreover, except for Cys27 the cys-
teines were individually replaced by alanines. Cys40, Cys57,
Cys72 and Cys104 are required for the cotransport with the
CLR to the cell surface, as well as for [125I]hKCGRP binding
and CGRP-evoked stimulation of cAMP formation in CLR/
hRAMP1-expressing cells.
2. Materials and methods
2.1. Materials
Human KCGRP(1^37) was purchased from Bachem (Bubendorf,
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Switzerland). Restriction enzymes were obtained from Promega
(Madison, WI, USA). 125I, ECL Western blot detection reagents
and Hybond ECL nitrocellulose membranes were from Amersham
Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK). Cell cul-
ture products were supplied by Invitrogen (Carlsbad, CA, USA) and
linear polyethyleneimine (PEI) (25 kDa) by Polysciences (Warrington,
PA, USA). Mouse antibodies to myc and to V5 epitopes were from
Invitrogen and Cy3-labelled sheep anti-mouse antibodies from Sigma
(St. Louis, MO, USA). Other chemicals and reagents were purchased
from Sigma and Merck at the highest grade available.
2.2. DNA constructs
The cDNA encoding myc-hRAMP1, cloned into pcDNA3 (Invitro-
gen), was provided by S. Foord (GlaxoSmithKline, Stevenage, Hert-
fordshire, UK). Myc-hRAMP1 had the amino acids 1^26 of the pre-
dicted signal sequence of hRAMP1 replaced by the CD33 signal
sequence [13] and fused to the myc epitope tag [Glu-Gln-Lys-Leu-
Ile-Ser-Glu-Glu-Asp-Leu-Leu] for cell surface detection. Gly-Ser
were encoded by a BamHI restriction site that was used for construc-
tion. Thus, the hRAMP1 amino acid sequence in myc-hRAMP1 starts
at Cys27 of wild-type hRAMP1. Along these lines, the neural network
and the hidden Markow model, using the SignalP V2.0 software
(www.cbs.dtu.dk/services/SignalP-2.0), predicted signal sequence
cleavage in wild-type hRAMP1 between Cys27 and Glu28. For further
truncation of the N-terminus of hRAMP1, deletions of Cys27 (myc-
hRAMP1v1) and of Cys27^Asn31 (myc-hRAMP1v5), Cys27^Arg37
(myc-hRAMP1v11) and Cys27^Asp47 (myc-hRAMP1v21) were intro-
duced into myc-hRAMP1 with a polymerase chain reaction (PCR)-
based approach. Brie£y, 5P-primers with a BamHI restriction site at
the 5P-end were designed to anneal at the desired positions in the
hRAMP1 coding sequence. The 3P-primer with a XhoI restriction
site at the 5P-end was complementary to the DNA sequence encoding
the six amino acids of the C-terminus of hRAMP1 and the stop
codon. The PCR products ampli¢ed with cloned Pfu DNA polymer-
ase (Promega) in 25 cycles were digested with BamHI and XhoI re-
striction enzymes, gel-puri¢ed and cloned into BamHI/XhoI-digested
pcDNA3 in frame with the coding sequence for the CD33 signal pep-
tide (CD33) and the myc epitope tag encoded upstream of the BamHI
restriction site. All the DNA fragments encoding CD33-myc fused to
mutated hRAMP1 were sequenced in both directions.
Mutagenesis with the QuikChange0 Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA), replacing cysteines 40, 57, 72, 82
and 104 in the hRAMP1 extracellular domain by alanine, revealed
myc-hRAMP1-C40A, -C57A, -C72A, -C82A and -C104A. The muta-
tions were introduced into the CD33-myc-hRAMP1 coding sequence
subcloned into EcoRV/XhoI-digested pBluescript SK vector (Strata-
gene). PCR ampli¢cation with pairs of primers containing the nucle-
otide substitutions was carried out with cloned Pfu DNA polymerase
(Promega). The products obtained after 30 cycles were gel-puri¢ed,
digested with DpnI restriction enzyme and ligated. The CD33-myc-
hRAMP1 coding sequences with the introduced mutations were veri-
¢ed by sequencing in both directions, and subsequently excised from
the SK vector with EcoRV and XhoI restriction enzymes and cloned
into EcoRV/XhoI-digested pcDNA3.
The DNA encoding the hCLR with an N-terminal V5 epitope tag
[Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr] (V5-
hCLR) was constructed as described [7].
2.3. Cell culture and transfection
COS-7 cells were grown at 37‡C in a humidi¢ed atmosphere of 95%
air and 5% CO2 in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
(4.5 g/l glucose) and Ham’s F12 (1:1) medium containing 2 mM
glutamine and 10% foetal calf serum. Simian virus 40 T-antigen-trans-
formed human embryonic kidney (TSA) cells were grown under the
same conditions in cell culture medium supplemented with 400 Wg/ml
geneticin. The cells were grown to 40^60% con£uence and transfected
with indicated concentrations of myc-hRAMP1 and V5-hCLR expres-
sion constructs and linear PEI [14]. Brie£y, 0.2 Wg/cm2 plasmid DNA
was diluted with 6.25 Wl/cm2 cell culture medium. This solution was
then combined with 0.5 Wg/cm2 PEI in 6.25 Wl/cm2 cell culture me-
dium, and vortexed immediately. After incubation for 15 min at room
temperature the volume of the DNA/PEI mixture was adjusted to 125
Wl/cm2 with cell culture medium and added to the cells. The cells were
incubated at 37‡C for 16^24 h. The volume was then increased to 250
Wl/cm2 with cell culture medium, and the cells were incubated for
another 48 h.
2.4. [125I]hKCGRP binding and cAMP stimulation
[125I]hKCGRP was prepared by a modi¢ed chloramine T method
and subsequent puri¢cation by high performance liquid chromatog-
raphy [15,16]. Binding was carried out in 24-well plates at 15‡C for 2 h.
The cells were incubated with 1700 Bq/well (60 pM) [125I]hKCGRP in
200 Wl/well DMEM/Ham’s F12 supplemented with 0.1% bovine serum
albumin (BSA) and 2 mM glutamine (binding medium) in the absence
and presence of 1 WM non-labelled hKCGRP. The cells were washed
once with 500 Wl binding medium, lysed with 500 Wl 0.5% sodium
dodecyl sulfate (SDS), and the lysates were counted in a Q-counter
(Kontron, Switzerland). Binding in the presence of 1 WM hKCGRP,
always lower than 20%, was considered non-speci¢c and was sub-
tracted from total binding for the calculation of speci¢c binding.
Cyclic AMP stimulation was performed in binding medium supple-
mented with 1 mM isobutylmethylxanthine (IBMX) for 15 min at
37‡C as described [15].
2.5. Immunocytochemistry
COS-7 cells were seeded on cover slides in 24-well plates and 48 h
later transfected with the V5-hCLR and the indicated wild-type and
mutant myc-hRAMP1 expression constructs. Cell surface and total
expression of wild-type and mutant myc-hRAMP1 was estimated
48 h after transfection by myc-immuno£uorescent staining of intact
and saponin-permeabilised cells, respectively. Brie£y, the cells were
¢xed with 4% formalin in phosphate-bu¡ered saline (PBS) for 20
min at room temperature, washed with PBS and incubated with im-
munostaining medium (DMEM/Ham’s F12 (1:1), 0.1% BSA) in the
absence (surface staining) or presence (total staining) of 0.1% saponin
for 30 min at room temperature. The cells were then incubated for 2 h
at room temperature with mouse antiserum to myc (diluted 1:300) in
200 Wl immunostaining medium in the absence or presence of saponin.
The cells were washed three times with the immunostaining medium
and then incubated with Cy3-labelled sheep anti-mouse antiserum
(1:200 ¢nal dilution) (Sigma) for 30 min. After three additional
washes the slides were mounted with Immu-Mount (Shandon Scien-
ti¢c, Pittsburgh, PA, USA). The cells were viewed with an Eclipse
E600 Nikon microscope (Ku«snacht, Switzerland) equipped with a
Plan Fluor 20U/0.5 DLL objective, a G-2A ¢lter and a Kappa
DX20 CCD camera (Gleichen, Germany) connected to the micro-
scope with a Nikon 0.45U projection lens. Immuno£uorescence of
intact and saponin-permeabilised cells was recorded with a Nikon
U-III multipoint sensor system and respective reciprocal exposure
times were taken as a measure for cell surface and total expression
of wild-type and mutant myc-hRAMP1.
2.6. Western blot analysis
TSA cells grown in 100-mm tissue culture dishes were transiently
transfected with indicated combinations of V5-hCLR and wild-type
and mutant myc-hRAMP1 expression constructs. Forty-eight hours
after transfection the cells were detached with 0.05% EDTA in PBS
and washed with PBS. 2U107 cells were lysed in 200 Wl 50 mM
HEPES (pH 7.5), 140 mM NaCl, 0.5% Triton X-100, 1 mM phenyl-
methylsulphonyl £uoride, 3 Wg/ml aprotinin, 3 Wg/ml leupeptin. The
cell lysates were cleared by centrifugation for 5 min at 20 000Ug and
70 Wl 4USDS^polyacrylamide gel electrophoresis (PAGE) loading
bu¡er was added. Proteins in cell lysates were separated by SDS^
PAGE (15% gel) and electrotransferred to nitrocellulose Hybond0
ECL0 membranes (Amersham, Piscataway, NJ, USA) in a Trans-
Blot cell (Bio-Rad, Hercules, CA, USA) overnight at 10 V and 4‡C.
Immunoblots were blocked with 5% low-fat milk and the epitope-
tagged proteins were visualised by enhanced chemiluminescence with
horseradish peroxidase (HRP)-labelled monoclonal myc (1:2000) and
V5 antibodies (1:5000) (Invitrogen) using the VersaDoc0 Imaging
System (Bio-Rad). Actin as a reference protein for the amount of
loaded cell lysates was visualised with monoclonal antibodies to actin
(1:3500) (Chemicon, Temecula, CA, USA) and secondary HRP-con-
jugated sheep antibodies to mouse immunoglobulins (1:5000) (Amer-
sham).
2.7. Data analysis
In binding inhibition and cAMP stimulation experiments half-max-
imal inhibition concentrations (IC50) and e¡ective concentrations
(EC50) of hKCGRP were calculated by non-linear regression analysis
using the FigP 6.0 software (Biosoft, Cambridge, UK). Results are
meansTS.E.M. Comparison to controls was carried out using the
FEBS 27855 19-11-03 Cyaan Magenta Geel Zwart
S. Steiner et al./FEBS Letters 555 (2003) 285^290286
Student’s t-test. P values of 6 0.05 were considered statistically sig-
ni¢cant.
3. Results
3.1. [125I]hKCGRP binding and cAMP formation of the hCLR
coexpressed with hRAMP1 deletion or cysteine/alanine
substitution mutants
The deletions introduced into the extreme N-terminus of
myc-hRAMP1 removed Cys27 (myc-hRAMP1v1) or the se-
quences Cys27^Asn31 (myc-hRAMP1v5), Cys27^Arg37 (myc-
hRAMP1v11) or Cys27^Asp47 (myc-hRAMP1v21) including
the second cysteine in position 40. Substitution of individual
cysteine residues in the extracellular domain of hRAMP1 re-
vealed myc-hRAMP1-C40A, -C58A, -C72A and -C104A.
Myc-hRAMP1 and the mutants were transiently coexpressed
with the hCLR in COS-7 cells. Speci¢c [125I]hKCGRP binding
in cells expressing the hCLR with intact myc-hRAMP1 was
10.4T 0.7% of added radioligand, set to 100% and de¢ned as
maximal binding (Fig. 1). [125I]hKCGRP binding was indistin-
guishable from maximal binding in cells expressing the hCLR
together with myc-hRAMP1v1 or -v5, but it was reduced to
15T 1% (n=4; P6 0.001) of maximal [125I]hKCGRP binding
with myc-hRAMP1v11 and indistinguishable from non-spe-
ci¢c [125I]hKCGRP binding with myc-hRAMP1v21 also lack-
ing Cys40. Speci¢c [125I]hKCGRP binding was similarly
suppressed with individual Cys40, Cys57 or Cys104 to Ala sub-
stitutions in the extracellular domain of myc-hRAMP1. Sub-
stitution of Cys72 or Cys82 to Ala decreased [125I]hKCGRP
binding to 13T 3% (n=5, P6 0.001) and 64T 6% (n=6,
P6 0.005) of maximal binding. [125I]hKCGRP binding in
hCLR/myc-hRAMP1-, -v1-, -v5- and -C82A-expressing cells
was inhibited by hKCGRP at indistinguishable IC50 (Table 1).
In COS-7 cells coexpressing the hCLR with intact myc-
hRAMP1 hKCGRP stimulated cAMP formation with an
EC50 of 0.19 T 0.04 nM and the 49T 7-fold increase over basal
levels with 1 WM hKCGRP was considered maximal and set to
100% (Fig. 2, Table 1). The cAMP response was the same in
cells coexpressing the hCLR with myc-hRAMP1-C82A and
with myc-hRAMP1v1 and -v5. Interestingly, further trunca-
tion by 11 amino acids in myc-hRAMP1v11 maintained the
maximal stimulation of cAMP by hKCGRP, but the EC50 was
increased nine-fold. Decreased a⁄nity for hKCGRP explains
the observed reduced [125I]hKCGRP binding in hCLR/myc-
hRAMP1v11-expressing cells. Conversely, substitution of
Cys40 and Cys72 to Ala minimally a¡ected the EC50 of
hKCGRP but the maximal cAMP response in hCLR/myc-
hRAMP1-C40A- or -C72A-expressing cells decreased to
14T 1% and 33T 2%, respectively. Moreover, the stimulation
of cAMP formation by hKCGRP was abolished in cells ex-
pressing the hCLR with the myc-hRAMP1 Cys27^Asp47 dele-
tion or the Cys57 or Cys104 to Ala substitution mutants. Taken
together, the deletion of up to ¢ve amino acids in the extreme
N-terminus including Cys27 or the substitution of Cys82 in the
extracellular domain of hRAMP1 did not a¡ect the CGRP
receptor function of the hCLR. More extended deletions in
the N-terminal region of up to 21 amino acids, including
Cys40, or the substitution of Cys40, Cys57, Cys72 and Cys104
in the extracellular domain of hRAMP1 impaired or abol-
ished the CGRP receptor function of the coexpressed hCLR.
Fig. 1. [125I]hKCGRP binding to intact and mutant myc-hRAMP1/
hCLR in COS-7 cells. COS-7 cells were co-transfected with hCLR
and indicated myc-hRAMP1. The cells were incubated for 2 h at
15‡C with 60 pM [125I]hKCGRP (1.5U1014 Bq/mmol) in the absence
(total binding) or presence (non-speci¢c binding) of 1 WM hKCGRP.
Speci¢c [125I]hKCGRP binding (total minus non-speci¢c binding) in
cells cotransfected with the hCLR and myc-hRAMP1 (wt) was
1.3T 0.1 fmol/200 000 cells (n=13) and was set to 100%. The results
are meansTS.E.M. of at least four independent experiments.
Table 1
[125I]hKCGRP binding inhibition and stimulation of cAMP forma-
tion by hKCGRP in COS-7 cells expressing the hCLR together with
intact myc-hRAMP1 and the indicated mutants
IC50 (nM) EC50 (nM)
myc-hRAMP1 19T4 (6) 0.19T0.04 (8)
-v1 16T3 (4) 0.26T0.07 (5)
-v5 16T4 (3) 0.20T0.06 (4)
-v11 n.d. 1.53T0.24 (4)
-v21 n.d. n.s. (3)
-C40A n.d. 0.77T0.12 (3)
-C57A n.d. n.s. (3)
-C72A n.d. 0.27T0.03 (3)
-C82A 18T1 (3) 0.27T0.03 (3)
-C104A n.d. n.s. (3)
Results are meansTS.E.M. with numbers of experiments in paren-
theses; n.d., not determinable at up to 1 WM hKCGRP; n.s., no
cAMP stimulation at up to 1 WM hKCGRP.
Fig. 2. Stimulation of cAMP formation by hKCGRP. COS-7 cells
were transfected with constructs for expression of the hCLR togeth-
er with myc-hRAMP1 (wt) or the indicated deletion (left) or Cys to
Ala substitution (right) mutants. The cells were incubated for 15
min at 37‡C with hKCGRP in the presence of IBMX. In cells ex-
pressing hCLR/myc-hRAMP1 1036 M hKCGRP stimulated cAMP
formation 49T7-fold (n=9) and was set to 100%. Basal cAMP lev-
els ranged from 1 to 2 pmol/200 000 cells. The results are means of
at least three independent experiments.
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3.2. Total and cell surface expression of hRAMP1 deletion and
cysteine/alanine substitution mutants
Impaired expression and cell surface delivery of mutant
myc-hRAMP1 were considered as mechanisms for defective
receptor function of the coexpressed hCLR. Expression of
myc-hRAMP1 and the mutants was estimated by myc immu-
no£uorescence staining of saponin-permeabilised COS-7 cells
coexpressing the V5-hCLR (Fig. 3) and by myc immunoche-
miluminescence on Western blots of extracts of corresponding
cells (Fig. 4). Myc immuno£uorescence of permeabilised cells
and Western blot analysis of total cell extracts revealed com-
parable expression levels of myc-hRAMP1 and of all the mu-
tants. The apparently faster migration on SDS^PAGE of
myc-hRAMP1v5 as compared to myc-hRAMP1v11 cannot
be explained. Extensive DNA sequencing of the correspond-
ing constructs con¢rmed their predicted amino acid sequence.
The expression of myc-hRAMP1 and of its mutants at the
cell surface was visualised and quanti¢ed by myc immuno£uo-
rescence staining of intact cells (Fig. 3). Indistinguishable cell
surface expression was observed for myc-hRAMP1 and the
-v1, -v5 and -C82A mutants, but the levels of myc-
hRAMP1v11 and -C72A were only 18T 1% and 24T7%
of myc-hRAMP1 and those of myc-hRAMP1v21, -C40A,
-C57A and -C104A were below 10%. Thus individual substi-
tution by alanine of the second, third, fourth and the sixth
cysteine in the extracellular domain of hRAMP1 impaired or
abolished its transport to the cell surface in the presence of the
hCLR. Deletions of 11 or 21 amino acids at the N-terminus of
hRAMP1 had similar e¡ects.
3.3. Suppression of hCLR glycosylation by hRAMP1
mutations
RAMP1-dependent posttranslational modi¢cation of core
to mature N-glycosylated hCLR in mammalian cells has
Fig. 3. Cell surface and total expression of intact and mutant myc-hRAMP1 in COS-7 cells revealed by myc immuno£uorescent staining. Cells
cotransfected with the hCLR and the indicated myc-hRAMP1 expression constructs were ¢xed with 4% formalin. Intact (surface) or saponin-
permeabilised (total) cells were stained with mouse anti-myc serum and Cy3-labelled antibodies to mouse IgG. Cy3 £uorescence was recorded
at a constant exposure time of 550 ms. A: Scale bar 100 Wm. Representative experiment carried out three times. B: Cell surface (open bars)
and total (closed bars) Cy3 immuno£uorescence in A was quanti¢ed as described in Section 2. Inverse exposure times in control pcDNA3-
transfected cells, re£ecting background £uorescence, ranged from 0.1 to 0.2 min31 in non-permeabilised and from 0.2 to 0.4 min31 in permeabi-
lised cells and were subtracted from individual measurements. The values obtained for wild-type (wt) myc-hRAMP1 in non-permeabilised cells
ranged from 1.9 to 3.5 min31 and were set to 100%. The results are meansTS.E.M. of three independent experiments.
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been well documented. The corresponding increase in size of
the V5-hCLR from 50^60 kDa in the absence of myc-
hRAMP1 to 73 kDa in its presence was con¢rmed in the
present study (Fig. 4). Maturation of the V5-hCLR was not
a¡ected by the myc-hRAMP1v1, -v5, -v11 and -C82A muta-
tions, but mature N-glycosylation of the V5-hCLR was sup-
pressed by the myc-hRAMP1v21, -C40A, -C57A, -C72A and
-C104A mutations. Interestingly, mature N-glycosylation of
the V5-hCLR required the expression of the myc-hRAMP1
mutants at the cell surface. Even diminished cell surface ex-
pression levels of myc-hRAMP1v11 and C72A were su⁄cient
for at least partial mature N-glycosylation of the coexpressed
V5-mCLR. Thus, mature N-glycosylation of the hCLR in
mammalian cells appears to require its cotransport with
hRAMP1 to the cell periphery.
4. Discussion
The extracellular domains of RAMP1 and -3 consist of
approximately 90 amino acids. They have in common six
conserved cysteine residues. RAMP2 lacks the ¢rst and the
¢fth cysteine of RAMP1 and -3 and the remaining four con-
served cysteines are required for delivery to the cell surface
and for AM receptor function of hCLR/hRAMP2 hetero-
dimers [9]. Cell surface and functional expression of mouse
RAMP3 in the presence of mouse CLR, on the other hand,
was not greatly a¡ected by individual substitutions of cys-
teines by serines when expressed in Xenopus oocytes [17]. Sub-
stitution of the N-terminal 24 amino acids of hRAMP1 by the
corresponding amino acids of hRAMP2 abolished CGRP-
stimulated cAMP formation [12]. This suggests that the ex-
treme N-terminus of hRAMP1, which includes the ¢rst and
the second cysteines, is required for CGRP receptor function
of the hCLR/hRAMP1 complex.
Here, the extreme N-terminus of myc-hRAMP1 including
the ¢rst and the second cysteines, Cys27 and Cys40, was pro-
gressively truncated. Moreover, Cys40, Cys57, Cys72, Cys82 and
Cys104 were each replaced by alanine. The e¡ects of the mu-
tations on the expression of myc-hRAMP1 at the cell surface
and on CGRP receptor function of the coexpressed hCLR
have been analysed. The deletion of Cys27 or of ¢ve amino
acids from Cys27 to Asn31 of hRAMP1 maintained CGRP
receptor function of the hCLR. This is in accordance with
results obtained with a v28^33 deletion mutant of hRAMP1
[18]. Additional deletion of 11 or 21 amino acids, with the
latter also removing the second conserved cysteine in position
40, impaired or abolished the expression of myc-hRAMP1
at the cell surface and, as a result, CGRP receptor function
of the hCLR. This con¢rms the functional defect of a
hRAMP2/1 chimera with 24 N-terminal amino acids of
hRAMP2 replacing the corresponding sequence of hRAMP1
[12]. Altogether, the results indicate that hRAMP1 function
tolerates only minimal N-terminal truncation.
The loss of function of myc-hRAMP1v21 suggested that
the second cysteine in position 40, unlike Cys27, may be im-
portant for myc-hRAMP1 function and forms a disulphide
bridge with one of the four more C-terminal conserved cys-
teines. This was investigated by individual substitutions of
Cys40, Cys57, Cys72, Cys82 and Cys104 by Ala. The Cys82 to
Ala substitution, much like the Cys27 deletion, maintained the
myc-hRAMP1 function, but the Cys40, Cys57, Cys72 and
Cys104 to Ala substitutions severely impaired or suppressed
delivery of myc-hRAMP1 to the cell surface and as a conse-
quence CGRP receptor function of the coexpressed hCLR.
Interestingly, Cys40, Cys57, Cys72 and Cys104, unlike Cys27
and Cys82 of hRAMP1, correspond to the four conserved
cysteines in hRAMP2 shown to be required for AM receptor
function of the coexpressed hCLR. This suggests that correct
folding of the extracellular domain of hRAMP1 and -2 in the
functional complex with the hCLR includes the formation of
disulphide bridges between pairs of cysteine residues. At
present the disulphide pairing cannot be assigned. From the
observed residual cAMP stimulation of hCLR/myc-hRAMP1-
C40A and -C72A heterodimers and the inactive hCLR in the
presence of myc-hRAMP1-C57A or -C104A the formation of
disulphide bonds between Cys40 and Cys72 and between Cys57
and Cys104 in hRAMP1 may tentatively be implied.
The suppressed transport of myc-hRAMP1v21, -C40A,
-C57A and -C104A, moreover, impairs posttranslational ma-
ture N-glycosylation of the initially core-glycosylated hCLR.
The hCLR on its way to the cell surface appears to bypass the
machinery for mature glycosylation in the Golgi in the ab-
sence of wild-type hRAMP1 or in the presence of defective
hRAMP1 mutants.
In conclusion, hRAMP1 can only be minimally truncated at
its extreme N-terminus and four out of six cysteine residues
also conserved in the extracellular domain of hRAMP2 are
required for the functional interaction with the hCLR to form
a hCLR/hRAMP1 CGRP receptor complex. The four con-
served cysteine residues are essential for cell surface delivery
of hRAMP1. Two disulphide bridges in the extracellular do-
main of hRAMP1 are possibly formed during maturation of
the hCLR/hRAMP1 CGRP receptor.
Fig. 4. Expression levels of V5-hCLR and myc-hRAMP1 and its
mutants. Lysates of TSA cells transfected with V5-hCLR alone or
cotransfected with V5-hCLR and myc-hRAMP1 or mutant expres-
sion constructs were separated by SDS^PAGE (15%) and the pro-
teins were electroblotted to nitrocellulose. The V5-CLR and myc-
hRAMP1 (wt) and the indicated mutants were visualised with HRP-
labelled antibodies to V5 or myc. Actin as a reference for protein
loading was estimated with mouse antibodies to actin and secondary
HRP-conjugated antibodies to mouse IgG. Arrows indicate the posi-
tion of protein size markers. Representative experiment carried out
three times.
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